ATE259826T1 - Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase - Google Patents

Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase

Info

Publication number
ATE259826T1
ATE259826T1 AT99914958T AT99914958T ATE259826T1 AT E259826 T1 ATE259826 T1 AT E259826T1 AT 99914958 T AT99914958 T AT 99914958T AT 99914958 T AT99914958 T AT 99914958T AT E259826 T1 ATE259826 T1 AT E259826T1
Authority
AT
Austria
Prior art keywords
side chain
transferase inhibitors
farnesyl transferase
functionalized alkyl
alkenyl side
Prior art date
Application number
AT99914958T
Other languages
English (en)
Inventor
Annette Marian Doherty
James Stanley Kaltenbronn
Daniele Marie Leonard
Dennis Joseph Mcnamara
John Quin Iii
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE259826T1 publication Critical patent/ATE259826T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99914958T 1998-04-27 1999-03-19 Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase ATE259826T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8325598P 1998-04-27 1998-04-27
PCT/US1999/006090 WO1999055725A1 (en) 1998-04-27 1999-03-19 Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors

Publications (1)

Publication Number Publication Date
ATE259826T1 true ATE259826T1 (de) 2004-03-15

Family

ID=22177160

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99914958T ATE259826T1 (de) 1998-04-27 1999-03-19 Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase

Country Status (15)

Country Link
US (1) US6369034B1 (de)
EP (1) EP1076663B1 (de)
JP (1) JP2002513031A (de)
KR (1) KR20010043035A (de)
AT (1) ATE259826T1 (de)
AU (1) AU759492B2 (de)
BR (1) BR9909961A (de)
CA (1) CA2322944C (de)
DE (1) DE69914893T2 (de)
DK (1) DK1076663T3 (de)
ES (1) ES2214021T3 (de)
NZ (1) NZ507165A (de)
PT (1) PT1076663E (de)
WO (1) WO1999055725A1 (de)
ZA (1) ZA200006035B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000034239A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン，エルエルシー Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
JP3837633B2 (ja) * 2002-11-19 2006-10-25 株式会社クレディアジャパン 新規な機能性ペプチド核酸およびその製法
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
DE10326303A1 (de) * 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
EP1660186B1 (de) 2003-08-18 2013-12-25 MedImmune, LLC Humanisierung von antikörpern
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1869192B1 (de) 2005-03-18 2016-01-20 MedImmune, LLC Rahmenmischung von antikörpern
US8987306B2 (en) * 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
AU2006254936A1 (en) * 2005-06-07 2006-12-14 The Trustees Of The University Of Pennesylvania Inhibitors of the alpha2beta1/GPIa-IIa integrin
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007027742A2 (en) * 2005-08-31 2007-03-08 The Trustees Of The University Of Pennsylvania SMALL MOLECULE INTEGRIN α2βl/GPIa-IIa ANTAGONISTS
EP2484696B1 (de) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistische hLIGHT-spezifische menschliche monoklonale Antikörper
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
EP2215246B1 (de) 2007-10-31 2015-01-07 MedImmune, LLC Proteingerüste
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP4063391A1 (de) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit-antikörper und verwendungen davon
SG11201502757QA (en) 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
EP3003390B1 (de) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54-antikörper und verwendungen davon
CN105764526B (zh) 2013-08-26 2020-12-15 生物技术研发公司 编码抗唾液酸化路易斯a抗原的人抗体的核酸
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
KR102693806B1 (ko) 2014-12-11 2024-08-09 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
KR102803158B1 (ko) 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
KR20250024129A (ko) 2018-07-20 2025-02-18 피에르 파브르 메디카먼트 Vista의 수용체
CN116113621A (zh) * 2020-07-22 2023-05-12 弗格制药有限公司 氨基酸

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2172125A1 (en) * 1993-09-30 1995-04-06 S. Jane Desolms Inhibitors of farnesyl-protein transferase
KR100362338B1 (ko) * 1993-11-05 2003-04-08 워너-램버트 캄파니 단백질:파르네실트랜스퍼라아제의치환디-및트리펩티드억제제
US5571792A (en) 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
WO1997044350A1 (en) 1996-05-22 1997-11-27 Warner-Lambert Company Inhibitors of protein farnesyl transferase
EP0951471B1 (de) 1996-12-17 2004-03-17 Warner-Lambert Company Llc Cycloalkyl inhibitoren der protein-farnesyltransferase
WO1998046625A1 (en) 1997-04-11 1998-10-22 Warner-Lambert Company Dipeptide inhibitors of protein farnesyltransferase

Also Published As

Publication number Publication date
DE69914893T2 (de) 2004-07-22
ZA200006035B (en) 2002-01-28
CA2322944C (en) 2003-05-20
AU3358799A (en) 1999-11-16
EP1076663A1 (de) 2001-02-21
PT1076663E (pt) 2004-06-30
US6369034B1 (en) 2002-04-09
ES2214021T3 (es) 2004-09-01
NZ507165A (en) 2003-06-30
DK1076663T3 (da) 2004-06-01
JP2002513031A (ja) 2002-05-08
AU759492B2 (en) 2003-04-17
WO1999055725A1 (en) 1999-11-04
EP1076663B1 (de) 2004-02-18
CA2322944A1 (en) 1999-11-04
BR9909961A (pt) 2000-12-26
KR20010043035A (ko) 2001-05-25
DE69914893D1 (de) 2004-03-25

Similar Documents

Publication Publication Date Title
DE69914893D1 (de) Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
DE69432614D1 (de) Alkohol und Aldehyde Derivate als Cathepsin L Inhibitore und als Inhibitore der Knochenresorption
ES2130930A1 (es) Recubrimientos y materiales de registro estabilizados con absorbentes de ultravioleta de benzotriazol.
LV12712A (lv) Inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodekstrin and method
IS6309A (is) Kínasólínafleiður
ATE430563T1 (de) Cyano-substituierte oleanolsäure als inhibitor der no-produktion
FI973217A0 (fi) Heteroaromaattisella renkaalla substituoituja antimikrobiaalisia fenyylioksatsolidinoniyhdisteitä
GB9801690D0 (en) Therapeutic agents
ATE263771T1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
EP1379251A4 (de) Hemmstoffe der akt aktivität
SI1000034T1 (en) Substituted 6-alkylphenanthridines
ATE248814T1 (de) 16-ene-vitamin d derivate
DK0668279T3 (da) 6-azaindol thromboxansytaseinhibitor
FI945290A0 (fi) Menetelmä ribonukleotidireduktaasi-inhibiittoreiden valmistamista varten
ATE265854T1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
NO20004477D0 (no) Anvendelse av organiske karbonater som løsningsmidler for vasking av metalloverflater
BR9908905A (pt) Novos compostos
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
AP2001002047A0 (en) Isoquinoliness as urokinase inhibitors.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1076663

Country of ref document: EP

REN Ceased due to non-payment of the annual fee